2017 – Scrip Readers’ Pharma Year In Review
Executive Summary
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
You may also be interested in...
The Year's Clinical Trials In Review: Big Hits In 2017
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
The Year's Clinical Trials In Review: Big Misses In 2017
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
EU Regulatory Review – What Pharma Should Remember From 2017
You could be forgiven for thinking that Brexit was the only story in town on the European regulatory front in 2017, but there were of course plenty of other important developments during the year.